
    
      This is a single arm, open-label, single-center study. This study is indicated for relapsed
      or refractory Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell
      Non-Hodgkin's Lymphoma. The selections of dose levels and the number of subjects are based on
      clinical trials of similar foreign products. 72 patients will be enrolled. Primary objective
      is to explore the safety, main consideration is dose-related safety.
    
  